Icon Biosciences announced that the Food and Drug Administration (FDA) has approved Dexycu (dexamethasone intraocular suspension) for the treatment of inflammation associated with cataract surgery.
Dexycu delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating the burden of self-administering medicated eye drops several times a day in a primarily elderly patient population.
In a press release, Eric D. Donnenfield, MD, New York University, and lead author of the Dexycu clinical studies said, “Dexycu is designed to improve the management of inflammation post cataract surgery. This novel ophthalmic medication offers the cataract surgeon the option of a single administration of a corticosteroid at the site of action. This, in turn, benefits patients by eliminating non-compliance and dosing errors associated with the current practice of relying on the patient dispensing frequent drops following cataract surgery.”
For more information visit IconBioscience.com.